Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Most relevant news about ROCHE HOLDING LTD.
05/25AstraZeneca cancer drug hits second goal by extending survival
RE
05/21Roche Presents Positive Results From Hemlibra Trials
DJ
05/21GENENTECH : ’s HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds by 96 Per..
BU
05/18AstraZeneca insists future is bright after big Crestor sales hit
RE
05/16Reducing Use of Roche Drug for Breast Cancer Didn't Hurt Efficacy, Study Says
DJ
05/16ROCHE : Phase III IMpower150 Study Showed Genentech’s TECENTRIQ and Avasti..
BU
05/16ROCHE : Follow-up Phase III Data Showed Genentech’s Alecensa Helped People..
BU
05/15Roche's Actemra Gets FDA Nod for Pediatric Subcutaneous Use
DJ
05/14ROCHE : FDA Approves Subcutaneous Formulation of Actemra for Use in Active Polya..
BU
05/14GENENTECH : to Present New Phase III Data for HEMLIBRA (emicizumab-kxwh) in Peop..
BU
05/10Roche's Phase 3 IMblaze370 Study Misses Primary Endpoint
DJ
05/10GENENTECH : Provides Update on Phase III Study of TECENTRIQ (Atezolizumab) and C..
BU
05/08GENENTECH : to Present New Data from its Industry-Leading Oncology Portfolio at ..
BU
05/07Roche's Tecentriq Gets FDA Priority Review in First-Line Lung Cancer Treatmen..
DJ
05/07ROCHE : FDA Grants Priority Review to Genentech’s Cancer Immunotherapy TEC..
BU
More most relevant news
All news about ROCHE HOLDING LTD.
05/25AstraZeneca cancer drug hits second goal by extending survival
RE
05/21Roche Presents Positive Results From Hemlibra Trials
DJ
05/21GENENTECH : ’s HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds by 96 Per..
BU
05/18AstraZeneca insists future is bright after big Crestor sales hit
RE
05/16Reducing Use of Roche Drug for Breast Cancer Didn't Hurt Efficacy, Study Says
DJ
05/16ROCHE : Phase III IMpower150 Study Showed Genentech’s TECENTRIQ and Avasti..
BU
05/16ROCHE : Follow-up Phase III Data Showed Genentech’s Alecensa Helped People..
BU
05/15Roche's Actemra Gets FDA Nod for Pediatric Subcutaneous Use
DJ
05/14ROCHE : FDA Approves Subcutaneous Formulation of Actemra for Use in Active Polya..
BU
05/14GENENTECH : to Present New Phase III Data for HEMLIBRA (emicizumab-kxwh) in Peop..
BU
More news
Sector news : Pharmaceuticals - NEC
05/25GRAIN HIGHLIGHTS : Top Stories of the Day
DJ
05/25LIVESTOCK HIGHLIGHTS : Top Stories of the Day
DJ
05/25ADRs End Lower; Major Oil Companies, Acorn International, and AstraZeneca Tra..
DJ
05/25Bayer cuts Monsanto synergy target by $300 million due to divestments
RE
05/25LONDON STOCK EXCHANGE : Oil weighs on FTSE, Kingfisher shines
RE
05/25Saudi Arabia to exclude German firms from government tenders - Spiegel
RE
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/25Roche Holding (RHHBY) Virtual Pipeline Event From WFH 2018 World Congress - S.. 
05/24AbbVie's Imbruvica + Roche's Gazyva successful in late-stage leukemia study 
05/23Roche Holding ADR (RHHBY) Presents At 2018 UBS Global Healthcare Conference -.. 
05/223Pea Is A Payment Processor With >40% Organic Growth Selling For Half Of Peer.. 
05/22Fibrogen Makes A Strong Case As An Acquisition Target After Latest Lung Fibro.. 
05/21Roche's Hemlibra reduced bleeds as much as 97% in late-stage study 
Latest Tweets
05/26What a stunning photo captured during the week by IG: seanhegarty_94 at Roche..
2
05/25Foundation Medicine $FMI Insider Sells $133,450.00 in Stock  
05/25Reminder: Invitation to Roche Analyst Event at ASCO 2018  
05/25Stocks to watch: Kingfisher, AstraZeneca, Imperial Brands, Roche  
05/25Stocks to watch: Kingfisher, AstraZeneca, Imperial Brands, Roche  
More tweets
Qtime:196
Financials ( CHF)
Sales 2018 55 741 M
EBIT 2018 18 660 M
Net income 2018 12 050 M
Debt 2018 4 564 M
Yield 2018 3,98%
P/E ratio 2018 15,07
P/E ratio 2019 14,52
EV / Sales 2018 3,45x
EV / Sales 2019 3,25x
Capitalization 188 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 262  CHF
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-9.17%189 708
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
NOVARTIS-8.30%194 397
MERCK AND COMPANY5.01%158 970
AMGEN2.33%117 942